This section captures essential metadata about the foreign counterparty, currency pair specifications, and transaction valuation parameters. Accurate completion is critical for regulatory reporting and risk management.
Foreign Entity Name
Foreign Entity Registration Number
Foreign Entity Jurisdiction
Relationship with Enterprise
Transaction Type
FX Forward Contract
Currency Swap
FX Forward with Optionality
Non-Deliverable Forward (NDF)
Settlement Type
Physical Delivery
Cash Settlement
Net Settlement
Optional Settlement
Base Currency (ISO 4217 Code)
Quote Currency (ISO 4217 Code)
Notional Amount in Base Currency
Equivalent Notional Amount in Quote Currency
Trade Date
Value Date (Settlement Date)
Maturity Date
Is this a rolling or extendable contract?
Transaction Complexity Rating (1=Simple, 5=Highly Complex)
ISDA Master Agreement in place with counterparty?
Market Data Snapshot at Trade Execution
Data Source | Spot Rate (Base/Quote) | Forward Points | Interest Rate Differential (%) | Quote Date & Time | |
|---|---|---|---|---|---|
Upload Executed Term Sheet or Trade Confirmation
Document the commercial rationale for this FX derivative transaction. This section must demonstrate a direct linkage between the hedge and an underlying commercial exposure to satisfy hedge accounting requirements and risk management policies.
Nature of Underlying Exposure
Foreign Currency Receivable
Foreign Currency Payable
Forecasted Transaction
Net Investment in Foreign Operation
Other
Commercial Contract Reference Number
Underlying Exposure Amount
Expected Cash Flow Date for Underlying Exposure
Detailed Description of Commercial Transaction
Has the underlying transaction been recognized in the accounting system?
Hedging Strategy Classification
Fair Value Hedge
Cash Flow Hedge
Net Investment Hedge
Economic Hedge (No Accounting Designation)
Risk Management Objective and Strategy
Does the hedge tenor match the underlying exposure timing?
Sources of Potential Hedge Ineffectiveness Identified
Credit Risk Differential
Timing Differences
Currency Notional Mismatch
Interest Rate Component
Counterparty Default Risk
Currency Basis Spread
No material ineffectiveness anticipated
Significance of Underlying Exposure to Enterprise (1 star=Immateral, 5 stars=Critical)
Cash Flow Timing Alignment Analysis
Cash Flow Event | Expected Date | Expected Amount | Currency | Covered by This Hedge? | |
|---|---|---|---|---|---|
Upload Underlying Commercial Contract or Purchase Order
Has this counterparty demonstrated historical payment/performance reliability?
Comprehensive pricing validation and counterparty risk assessment are mandatory. This section ensures fair value execution and compliance with counterparty risk limits.
Executing Bank / Financial Institution
Counterparty LEI (Legal Entity Identifier)
Executed Forward Rate (Base/Quote)
Mid-Market Reference Rate at Execution
Transaction Spread Cost (in Base Currency)
Spread in Basis Points
Is the spread within approved treasury policy limits?
Pricing Model Used
Covered Interest Rate Parity
Forward Point Model
Direct Market Quote
Black-Scholes (for options)
Internal Pricing Engine
Third-Party Vendor Model
Pricing Assumptions and Parameter Inputs
Has independent price verification (IPV) been performed?
Current Counterparty Credit Limit (Aggregate)
Proposed Utilization from This Transaction
Remaining Available Limit After This Transaction
Counterparty Credit Rating Score (S&P Equivalent Scale)
Collateralization Status
Uncollateralized
CSA in Place - No Threshold
CSA in Place - With Threshold
Initial Margin Posted
Variation Margin Only
Full Collateralization
Does this transaction exceed single counterparty concentration limits?
Potential Future Exposure (PFE) for This Transaction
Counterparty Risk Assessment Matrix
Very Low Risk | Low Risk | Moderate Risk | High Risk | Very High Risk | |
|---|---|---|---|---|---|
Credit Rating Stability | |||||
Regulatory Capital Adequacy | |||||
Historical Settlement Performance | |||||
Market Reputation | |||||
Geopolitical Risk Exposure |
Comparative Pricing Analysis - Multi-Dealer Quote
Quoting Institution | Forward Rate Offered | Spread Cost | Credit Quality Rating (1-5) | Selected for Execution? | |
|---|---|---|---|---|---|
Upload Pricing Screenshots and Dealer Quotes
Hedge accounting designation requires prospective and retrospective effectiveness testing. Complete this section to demonstrate compliance with IFRS 9 or ASC 815 requirements. Ineffectiveness may result in P&L volatility and financial statement impact.
Applicable Accounting Standard
IFRS 9 - Financial Instruments
ASC 815 - Derivatives and Hedging
Both IFRS 9 and ASC 815 (Dual Reporting)
Local GAAP Equivalent
No Hedge Accounting Designation
Has formal hedge documentation been prepared prior to trade execution?
Hedge Effectiveness Testing Methodology
Critical Terms Match
Regression Analysis
Dollar-Offset Ratio
Hypothetical Derivative Method
Volatility Reduction Measure
Risk Component Approach
Do critical terms of hedge and hedged item match exactly?
Prospective Effectiveness Assessment Result (%)
Key Assumptions in Prospective Effectiveness Test
Is retrospective effectiveness testing required for this reporting period?
Sources of Potential Hedge Ineffectiveness Identified
Counterparty Credit Risk
Interest Rate Differential Changes
Notional Amount Mismatch
Timing Differences
FX Forward Points Volatility
Currency Basis Spread
Optionality Component
No significant ineffectiveness expected
Will the hedge relationship be rebalanced during its life?
Hedge Designation Reference Number
Hedged Item Identification (Portfolio or Individual)
Hedge Effectiveness Metrics Assessment
Correlation Analysis | |
Dollar Offset Ratio | |
Regression R-Squared | |
Volatility Reduction | |
Critical Terms Alignment |
Is this hedge designated against a layer component of a portfolio?
Hedge Effectiveness Testing Results Summary
Test Type | Test Date | Effectiveness Ratio/Result | Passed Effectiveness Criteria? | Comments and Exceptions | |
|---|---|---|---|---|---|
Upload Complete Hedge Documentation Package
Has the hedge been assessed for any embedded derivatives requiring bifurcation?
Final authorization requires dual sign-off from Enterprise Treasury leadership and the CFO. By signing, approvers certify that all information is accurate, policy-compliant, and that appropriate risk assessments have been completed. This section is legally binding.
Full Name & Official Title
Approval Date & Time
I certify that this FX derivative transaction aligns with enterprise risk management policies and treasury guidelines.
I confirm that counterparty credit limits have been verified and are not exceeded post-execution.
I attest that pricing is consistent with market conditions and represents best execution under prevailing circumstances.
Additional Comments or Conditions
Head of Enterprise Treasury Signature
Full Name & Official Title
Approval Date & Time
I certify that the hedge accounting treatment has been reviewed and complies with applicable IFRS 9 or ASC 815 requirements.
I approve the financial risk undertaken by this transaction and confirm it is within the company's stated risk appetite and tolerance limits.
I acknowledge that this authorization creates legally binding obligations and that all regulatory reporting requirements have been considered.
Does this transaction require Board Audit Committee or Risk Committee notification?
Was delegated authority utilized for this approval (e.g., CFO authorized designee)?
Strategic Rationale and Final Approval Comments
Chief Financial Officer Signature
Upload Supporting Documentation Package (Approvals, Emails, Committee Minutes)
Emergency approval process invoked due to market timing?